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Abstract
Introduction Studies on the association between the
cytochrome P450c17α  gene (CYP17) 5'-untranslated region
MspA1 genetic polymorphism and breast cancer risk have
yielded inconsistent results. Higher levels of estrogen have been
reported among young nulliparous women with the A2 allele.
Therefore we assessed the impact of CYP17 genotypes on the
risk of premenopausal breast cancer, with emphasis on parity.
Methods We used data from a population-based case–control
study of women aged below 51 years conducted from 1992 to
1995 in Germany. Analyses were restricted to clearly
premenopausal women with complete information on CYP17
and encompassed 527 case subjects and 904 controls, 99.5%
of whom were of European descent. The MspA1 polymorphism
was analyzed using PCR-RFLP (PCR–restriction fragment
length polymorphism) assay.
Results The frequencies of the variant allele among the cases
and controls were 43% and 41%, respectively. Overall, CYP17
A1/A2 and A2/A2 genotypes compared with the A1/A1
genotype were not associated with breast cancer, with adjusted
odds ratios (ORs) of 1.04 and 1.23, respectively. Among
nulliparous women, however, breast cancer risk was elevated for
the A1/A2 (OR = 1.31; 95% confidence interval (CI) 0.74 to
2.32) and the A2/A2 genotype (OR = 2.12; 95% CI 1.04 to
4.32) compared with the A1/A1 genotype, with a trend towards
increasing risk associated with number of A2 alleles (P = 0.04).
Otherwise, the CYP17 polymorphism was found neither to be
an effect modifier of breast cancer risks nor to be associated
with stage of disease.
Conclusion Our results do not indicate a major influence of
CYP17 MspA1 polymorphism on the risk of premenopausal
breast cancer, but suggest that it may have an impact on breast
cancer risk among nulliparous women. The finding, however,
needs to be confirmed in further studies.
Introduction
The risk of breast cancer is related to genetic, environmental,
and lifestyle factors that influence the level of exposure to
estrogens and other sex hormones [1]. Regarding genetic fac-
tors, high-penetrance cancer-susceptibility genes such as
BRCA1 and BRCA2 are associated with some cases of famil-
ial breast cancer, though this association accounts for only
about 5% of all breast cancer cases [2], while low-penetrance
genes together with endogenous and lifestyle factors are likely
to account for a higher proportion of breast cancer cases [3].
These low-penetrance genes include genes involved in the
metabolism of sex hormones. One such gene is CYP17, which
codes for the enzyme cytochrome P450c17α , responsible for
catalyzing steroid 17α -hydroxylase and 17,20-lyase activities
at key branch points in the estrogen biosynthesis pathway [4].
An increase or decrease in activity of these enzymes may alter
the level of endogenous estrogen (estradiol), thereby influenc-
ing susceptibility to breast cancer [5,6]. One of the polymor-
phisms of the CYP17  gene is a thymidine substitution for
cytosine (T to C) giving rise to an MspA1 restriction site at
nucleotide 27 in the 5'-untranslated region (5'-UTR) promoter
[7]. The MspA1 polymorphism has three genotypes: a
CI = confidence interval; OR = odds ratio; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism; UTR = untranslated 
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homozygous wild type (A1/A1), a heterozygous variant (A1/
A2), and the homozygous variant (A2/A2) [6]. The T-to-C sub-
stitution was initially hypothesized to create an Sp-1 binding
site, which could lead to up-regulation of transcriptional acti-
vation of the variant allele and higher activity of the enzyme
[8,9], but this was not observed in experimental studies [10-
12].
The A2 allele has been associated with higher levels of estro-
gen than the wild-type allele [13,14]. In premenopausal
women, the A2 allele is also associated with higher levels of
dehydroepiandrosterone sulfate, and in postmenopausal
women, with higher levels of total estradiol [15]. Estrogen is a
known risk factor for breast cancer and many reproductive fac-
tors that are associated with risk, such as nulliparity, late age
at first pregnancy, early menarche, and late menopause, are
considered markers of lifetime exposure to estrogens [1]. It
has been hypothesized that the presence of the variant A2
allele could contribute to an increase in breast cancer risk by
virtue of higher estrogen levels. Several epidemiological stud-
ies have investigated the association between the CYP17
MspA1 polymorphism and breast cancer risk, with inconsist-
ent findings [16-19]. A systematic review of studies on CYP17
and breast cancer risk by Dunning and colleagues concluded
that risk was not significantly altered by CYP17 genetic poly-
morphisms [5]. In addition, a meta-analysis of 15 case–control
studies published between 1994 and 2001 showed that the
CYP17 MspA1 polymorphism may be a weak modifier of
breast cancer risk but is not a significant independent risk fac-
tor [6]. However, the meta-analysis failed to include one study
which, if included, could suggest a possible small increase in
risk of breast cancer associated with the A2 allele [20].
Ambrosone and colleagues [21] also found that CYP17 acts
as an effect modifier of breast cancer risk, especially with fac-
tors that influence endogenous estrogen levels. Similar to find-
ings of other studies, they reported a protective effect of late
age at menarche [8,13,22], and an increased risk with late age
at first full-term pregnancy and use of oral contraceptives,
among premenopausal women with the A1/A1 genotype.
It has been shown that premenopausal nulliparous women
with the A2/A2 genotype have higher mean levels of serum
estradiol than those with the A1/A1 genotype [14,23], imply-
ing that nulliparous women with the A2/A2 genotype may have
a higher risk of breast cancer than nulliparous women with the
A1/A1 genotype. Very few studies have looked at the risk of
breast cancer associated with CYP17  in relation to parity
[22,24]. This study therefore aimed to assess the risk of breast
cancer and CYP17 genotype according to parity (nulliparous
versus parous) and other risk factors for breast cancer among
premenopausal women.
Materials and methods
Study design and study population
We used data from a population-based case–control study
conducted from 1992 to 1995 in two regions of southern Ger-
many (Freiburg and the Rhein–Neckar–Odenwald regions)
[25]. The ethics committee of the University of Heidelberg
reviewed the study protocol, and subjects who participated
gave their informed consent. Subjects eligible for participation
were German speaking, were under 51 years of age, resided
within the study region, and had no previous history of breast
cancer. Cases newly diagnosed with either in-situ or invasive
breast cancer within the study period were identified through
frequent monitoring of hospital admissions, surgery sched-
ules, and pathology records from about 40 hospitals serving
the study regions. There were also periodic checks of pathol-
ogy institutions serving these hospitals, in order to identify any
overlooked cases. There were 1,020 eligible case subjects, of
whom 1,005 (98.5%) were alive when identified. Of these liv-
ing subjects, 706 (70.2%) completed the study questionnaire
and constituted the original population of case subjects, 152
(15.1%) refused to participate, 85 (8.5%) failed to respond,
51 (5.1%) were not contacted because of the physician's
refusal to allow contact, and 11 (1.1%) were unable to partic-
ipate because of health problems.
Controls were randomly selected from population registers of
the study regions. An attempt was made to recruit two popu-
lation controls per case, matched by age and study region.
Subjects were not eligible as controls if they could not speak
German, had moved out of the study region, had a previous
history of primary breast cancer, were mentally handicapped,
or had died. Of 2,257 eligible population controls, 1,381
(61.2%) participated (these were considered the original con-
trol population), 658 (29.1%) refused to participate, and 218
(9.7%) did not respond.
All subjects were asked to complete a self-administered ques-
tionnaire on demographic factors, anthropometric measures,
menstrual, reproductive, and breast feeding histories, use of
contraceptives and exogenous hormones, medical and
screening histories, first- and second-degree family history of
breast cancer, occupational exposures, smoking history, and
alcohol consumption. Information on exposure for cases and
controls was truncated at a reference date, which was the
date of diagnosis for cases and the date of completion of the
questionnaire for controls. All subjects were asked to provide
a blood sample, which was used for genotyping. The median
time between diagnosis and interview for cases was 2 months.
The study population was homogeneous, with 95.1% being of
German origin and 88.6% of the non-Germans being of Euro-
pean descent. A total of 99.5% of the sudy subjects (Germans
and non-Germans) were of European descent. The mean age
was 41.6 years (± 5.8 standard deviations) for the cases and
41.7 years (± 5.7 standard deviations) for the controls.Available online http://breast-cancer-research.com/content/7/4/R455
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Genotyping
Genomic DNA was extracted from the blood samples drawn
into ethylenediaminetetraacetic acid tubes using Blood and
Cell Culture DNA kits as described by the manufacturer (Qia-
gen GmbH, Hilden, Germany). The CYP17 5'-UTR MspAI pol-
ymorphism was analyzed using the previously described PCR-
RFLP assay [7]. Briefly, a PCR fragment containing the base-
pair change was amplified from genomic DNA by using prim-
ers (sense, 5'-CATTCGCACCTCTGGAGTC-3' ; antisense,
5'-GGCTCTTGGGGTACTTG-3'). After amplification, the
PCR products were digested with the restriction endonucle-
ase MspAI, subjected to electrophoresis through a 3% agar-
ose gel, and visualized by staining the gel with ethidium
bromide. Different genotypes could then be distinguished
based on the size of the digested fragments.
Statistical analysis
We restricted our analysis to women clearly defined as pre-
menopausal, since risk factors for breast cancer vary depend-
ing on menopausal status. Only women who still had
menstrual cycles or reported natural amenorrhea for less than
6 months or more before the reference date (date of diagnosis
for case subjects and date of completion of questionnaire for
controls) were considered premenopausal. Women who
reported natural amenorrhea 6 months before the reference
date or bilateral oophorectomy were considered postmeno-
pausal and hence not included in the analysis. Menopausal
status for those who reported hysterectomy alone was classi-
fied as unknown and these subjects were also excluded, leav-
ing 558 (79.0%) cases and 1,116 (80.8%) controls. Of these
premenopausal subjects, 527 case subjects (94.4%) and 904
controls (81.0%) had complete information on CYP17 geno-
type, and therefore these 527 cases and 904 controls were
included in the analysis.
The distribution of demographic characteristics and potential
risk factors of breast cancer in this study population was com-
pared with that of the original study population. Allele and gen-
otype frequencies among cases and controls were calculated
and deviation from Hardy–Weinberg equilibrium was exam-
ined using the χ 2 test. The distributions of potential risk factors
for breast cancer by CYP17 genotype in cases and controls
were compared. Odds ratios (ORs) and 95% confidence
intervals (95% CIs) were computed using multivariate condi-
tional logistic regression analysis. Maximum-likelihood esti-
mates were produced using the PHREG procedure in the
SAS statistical software package (release 8.2; SAS Institute
Inc, Cary, NC, USA). One-year age stratification was used to
optimize age adjustment. Assessment of the association
between CYP17 genotype and breast cancer was adjusted
for potential confounders, including age at menarche, having
ever used an oral contraceptive, total months of breastfeeding,
family history of breast cancer in first-degree relatives, parity
(defined as the number of full-term pregnancies resulting in
either a live or a stillbirth), age at first full-term pregnancy (for
parous women only), current body mass index, alcohol con-
sumption, and level of education. Other variables such as
study region, marital status, and smoking did not materially
affect the risk estimates and were therefore not included in the
model.
The effect of CYP17  genotype by parity (nulliparous and
parous) and by other risk factors was examined to identify dif-
ferential effects. We tested for trends in the logistic analyses
by categorizing the exposure variables and treating the scored
variables as continuous. All P values computed in the analyses
were two-tailed. We tested for multiplicative interaction by
computing the cross product of the variables and including it
in the model alongside its separate components. We also
assessed the distribution of the CYP17 genotype with respect
to stage of the disease (local: stages 1 and 2; advanced:
stages 3 and 4) and investigated trends with the Cochran–
Armitage test.
Results
There were no major differences in the distribution of demo-
graphic characteristics and potential risk factors of breast can-
cer between the original study population and this study
population (Table 1). Subjects in this study were about a year
younger than those in the originally selected population,
because we included only premenopausal women, who are
generally younger than the excluded postmenopausal women.
The frequency of the variant allele (A2) in the study population
was similar for the cases and the controls: 43% and 41%,
respectively. The genotype distribution was in agreement with
that predicted under Hardy–Weinberg equilibrium, for both
cases (P = 0.217) and controls (P = 0.380).
Table 2 shows the distribution of some risk factors for breast
cancer among case subjects and controls by CYP17 geno-
type.  χ 2 tests for distribution revealed no significant differ-
ences among cases and controls in any of the genotype
g r o u p s  ( A 1 / A 1 ,  A 1 / A 2 ,  A 2 / A 2 )  w i t h  r e s p e c t  t o  a g e  a t
menarche, age at first full-term pregnancy, parity, total months
of breastfeeding, current body mass index, and educational
level. Case subjects with the A1/A2 genotype were more likely
than controls with this genotype to have used oral contracep-
tives. Compared with controls, case subjects with the A1/A1
genotype had significantly more family history of breast cancer
and consumed more alcohol.
Overall, there was no significant association between the
CYP17 genetic polymorphism and breast cancer risk (Table
3). The odds ratios for A1/A2 and A2/A2 genotypes were
1.04 and 1.23, respectively, in comparison with the A1/A1
genotype. Stratification by parity revealed a significantly
increased risk in carriers of the A2/A2 genotype when com-
pared with the A1/A1 genotype among nulliparous women
(OR = 2.12). The risk associated with the A1/A2 genotype
was elevated but did not reach statistical significance (OR =Breast Cancer Research    Vol 7 No 4    Verla-Tebit et al.
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Table 1
Comparison of demographic characteristics and potential risk factors for breast cancer in two study populations
Population statistics and characteristics Present study population Original study populationa
Cases (n = 527) Controls (n = 904) Cases (n = 706) Controls (n = 1,381)
Mean age (years) at diagnosis or recruitment 41.6 41.7 42.5 42.6
Mean BMI (kg/m2) 24.0 23.9 24.1 24.2
Mean age (years) at menarche 13.1 13.1 13.1 13.1
Mean age (years) at first full-term pregnancyb 24.4 24.9 24.2 24.3
Population characteristics (%)
Study region
Rhein–Neckar–Odenwald 71.7 70.7 70.0 69.3
Freiburg 28.3 29.3 30.0 30.7
Marital statusc
Single 9.3 9.8 7.8 8.4
Married/with partner 81.0 80.0 81.2 78.3
Widowed, divorced or separated 9.7 10.2 10.9 13.2
Nationality
German 91.8 97.0 91.2 95.8
Non-German 8.2 3.0 8.8 4.2
Educational level
Low 13.5 11.7 14.7 14.2
Intermediate 63.7 60.7 63.3 60.3
High 22.8 27.6 22.0 25.5
Parity
0 23.5 22.0 21.7 20.8
1 27.7 24.1 29.0 24.5
2 39.5 37.5 38.5 38.0
3+ 9.3 16.4 10.8 16.7
Oral contraceptive used
No 16.1 19.7 18.1 19.8
Yes 83.9 80.1 81.9 80.0
Breastfeedingb
Never 28.8 26.5 31.3 29.2
Ever 71.2 73.5 68.7 70.8
First-degree family history of breast cancer
No 87.7 94.7 87.7 94.9
Yes 12.3 5.3 12.3 5.1
Daily average alcohol intake
0 g 20.7 16.4 21.7 17.3
1–18 g 65.6 74.5 63.8 74.1
>18 g 13.7 9.1 14.5 8.7
aAll who completed questionnaires. bLimited to parous women. cTwo controls from the original study population had unknown marital status. 
dThree controls from the original study and two controls from the present study have missing data. BMI, body mass index.Available online http://breast-cancer-research.com/content/7/4/R455
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Table 2
Distribution of breast cancer risk factors according to CYP17 genotype for premenopausal women in Germany
Patient characteristics CYP17 genotype
A1/A1 (n = 503) A1/A2 (n = 668) A2/A2 (n = 260)
Cases, no. (%) Controls no. (%) Cases, no. (%) Controls no. (%) Cases, no. (%) Controls no. (%)
Age at menarche (years)a
<13 68 (37.8) 123 (38.2) 84 (34.4) 149 (35.1) 34 (33.0) 51 (32.5)
≥ 13 112 (62.2) 199 (61.6) 158 (64.8) 275 (64.9) 68 (66.0) 106 (67.5)
Age at first full-term pregnancy (years)b
<25 69 (49.6) 125 (49.4) 106 (56.1) 172 (52.1) 40 (53.3) 55 (45.1)
≥ 25 70 (50.4)) 128(50.6) 83 (43.9) 158 (47.9) 35 (46.7) 67 (54.9)
Parity
0 birth 41 (22.8) 70 (21.7) 55 (22.5) 94 (22.2) 28 (27.2) 35 (22.3)
1–2 births 123 (68.3) 201 (62.2) 168 (68.9) 260 (61.3) 63 (61.2) 96 (61.1)
>2 births 16 (8.9) 52 (16.1) 21 (8.6) 70 (16.5) 12 (11.6) 26 (16.6)
Total months of breastfeedingb
0 43 (30.9) 65 (25.7) 53 (28.0) 94 (28.5) 20 (26.7) 28 (22.9)
1–12 86 (61.9) 156 (61.7) 117 (61.9) 186 (56.4) 50 (66.8) 74 (60.7)
>12 10 (7.2) 32 (12.6) 19 (10.1) 50 (15.2) 5 (6.7) 20 (16.4)
Ever use oral contraceptivec
No 30 (17.1) 62 (19.4) 31 (13.0) 84 (20.0)* 24 (23.3) 32 (20.5)
Yes 146 (82.9) 258 (80.6) 207 (87.0) 336 (80.0) 79 (76.7) 124 (79.5)
Family history of breast cancer in first-degree relative
No 150 (83.3) 306 (94.7)* 217 (88.9) 407 (96.0) 95 (92.2) 143 (91.1)
Yes 30 (16.7) 17 (5.3) 27 (11.1) 17 (4.0) 8 (7.8) 14 (8.9)
Current BMI (k/m2)d
<20.0 26 (14.4) 35 (10.8) 39 (16.0) 47 (11.1) 10 (9.7) 25 (15.9)
20.0–25.0 95 (52.8) 191 (59.1) 130 (53.3) 245 (57.8) 64 (62.1)) 87 (55.4)
25.1–30.0 38 (21.1) 71 (22.0) 51 (20.9) 95 (22.4) 20 (19.4) 30 (19.1)
>30.0 20 (11.1) 25 (7.7) 24 (9.8) 37 (8.7) 9 (8.7) 15 (9.6)
Educational level
Low 24 (13.4) 39 (12.1) 31 (12.7) 50 (11.8) 16 (15.5) 17 (10.8)
Middle 114 (63.3) 200 (61.9) 159 (65.2) 262 (61.8) 63 (61.2) 87 (55.4)
High 42 (23.3) 84 (26.0) 54 (22.1) 112 (26.4) 24 (23.3) 53 (33.8)
Alcohol consumption (g/day)
0 39 (21.7) 52 (16.1)* 52 (21.3) 72 (17.0) 18 (17.5) 24 (15.3)
1–18 118 (65.5) 246 (76.2) 158 (64.8) 309 (72.9) 70 (68.0) 119 (75.8)
>18 23 (12.8) 25 (7.7) 34 (13.9) 43 (10.1) 15 (14.5) 14 (8.8)
aData were missing for one control with A1/A1 genotype, two cases with A1/A2 genotype, and one case with A2/A2 genotype. bLimited to parous 
women. cData were missing for four cases and three controls with A1/A1 genotype; six cases and four controls with A1/A2 genotype, and one 
control with A2/A2 genotype. dData were missing for one case and one control with A1/A1 genotype. * χ 2 test, P < 0.05. BMI, body mass index.Breast Cancer Research    Vol 7 No 4    Verla-Tebit et al.
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1.31). There was a trend towards increasing risk with the
number of variant alleles carried, which was statistically signif-
icant among nulliparous women (P = 0.04) but nonsignificant
among parous women (P for interaction = 0.87) (Table 3).
Table 4 shows the joint effects of CYP17 genotypes and par-
ity. In comparison with parous women with the A1/A1 geno-
type, the greatest risk increase was seen for nulliparous
women with the A2/A2 genotype (OR = 1.48).
In Table 5, we show results regarding some potential risk fac-
tors of breast cancer by CYP17 genotype, both overall and
with further stratification by parity. Because of limited power
for subgroup analyses, we combined A1/A2 and A2/A2 gen-
otypes, as both groups are considered putative high-risk
groups. Late age at menarche was not associated with breast
cancer risk, irrespective of genotype and parity. The odds ratio
for nulliparous women with the A1/A1 genotype who had ever
used oral contraceptives was elevated compared with those
Table 3
Association between CYP17 genetic polymorphisms and premenopausal breast cancer risk by parity in Germany
CYP17 genotype Cases, no. (%) (n = 527) Controls, no. (%) (n = 904) Age-adjusted OR (95% CI)a Multivariate-adjused OR (95% CI)b
All subjectsc
A1/A1 180 (34.2) 323 (35.7) 1.00 1.00
A1/A2 244 (46.2) 424 (46.9) 1.02 (0.80–1.31) 1.04 (0.81–1.34)
A2/A2 103 (19.6) 157 (17.4) 1.18 (0.87–1.61) 1.23 (0.89–1.69)
Trend test P 0.34 0.24
Parous womend
A1/A1 139 (34.5) 253 (35.9) 1.00 1.00
A1/A2 189 (46.9) 330 (46.8) 1.02 (0.78–1.35) 1.04 (0.78–1.37)
A2/A2 75 (18.6) 122 (17.3) 1.13 (0.79–1.61) 1.14 (0.79–1.65)
Trend test P 0.54 0.50
Nulliparous women
A1/A1 41 (33.0) 70 (35.2) 1.00 1.00
A1/A2 55 (44.4) 94 (47.2) 1.23 (0.72–2.07) 1.31 (0.74–2.32)
A2/A2 28 (22.6) 35 (17.6) 1.74 (0.90–3.38) 2.12 (1.04–4.32)
Trend test P 0.11 0.04
aAge-adjusted odds ratio (OR) and 95% confidence interval (CI). bMultivariate-adjusted OR and 95% CI. Adjusted for age at menarche in years (≤  
12, 13 to 14, 15+); total months of breastfeeding (0, 1 to 12, >12); alcohol consumption (0, 1–18, >18 g/day); current body mass index as 
continuous variable; educational level (low, middle, high); and family history of breast cancer in first-degree relative (no, yes); oral contraceptive 
use (no, yes). cAlso adjusted for parity (0, 1 to 2 births, 3+ births). dAlso adjusted for age at first full-term pregnancy (<25, ≥  25 years). P for 
interaction = 0.87.
Table 4
Joint effects of CYP17 polymorphisms and parity on risk of premenopausal breast cancer in Germany
CYP17 genotype Cases, no. (%) Controls, no. (%) OR (95% CI)a OR (95% CI)b
Parous women
A1/A1 139 (26.4) 253 (28.0) 1.00 1.00
A1/A2 189 (35.9) 330 (36.5) 1.03 (0.78–1.36) 1.05 (0.79–1.39)
A2/A2 75 (14.2) 122 (13.5) 1.12 (0.79–1.60) 1.16 (0.80–1.66)
Nulliparous women
A1/A1 41 (7.8) 70 (7.7) 1.04 (0.67–1.61) 1.01 (0.62–1.67)
A1/A2 55 (10.4) 94 (10.4) 1.04 (0.70–1.56) 1.05 (0.66–1.67)
A2/A2 28 (5.3) 35 (3.9) 1.43 (0.83–2.46) 1.48 (0.82–2.70)
aAge-adjusted odds ratio (OR) and 95% confidence interval (CI). bMultivariate adjusted OR and 95% CI. Adjusted for age at menarche in years (≤  
12, 13 to 14, 15+); oral contraceptive use (no, yes); total months of breastfeeding (0, 1 to 12, >12); alcohol consumption (0, 1 to 18, >18 g/day); 
current body mass index as continuous variable; educational level (low, middle, high).Available online http://breast-cancer-research.com/content/7/4/R455
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who had never used oral contraceptives (OR = 2.60). The
effect of breastfeeding among parous women (those who had
ever breastfed versus those who had never breastfed) did not
differ by genotype. However, among the parous women who
had ever breastfed, breastfeeding for more than 12 months
was associated with a risk reduction (OR = 0.56) when com-
pared with 1 to 12 months of breastfeeding (Table 5). This
effect did not differ according to CYP17 genotype (P for inter-
action = 0.48). Age at first full-term pregnancy was not asso-
ciated with breast cancer risk in this study and the result was
not altered when genotype status was taken into
consideration.
Table 5
Association between some potential risk factors of breast cancer by CYP17 genotype among premenopausal women in Germany
Factor All data A1/A1 A1/A2 and A2/A2
Cases (n = 
527)
Controls (n = 
904)
ORa (95% 
CI)
Cases (n = 
180)
Controls (n = 
323)
ORa (95% CI) Cases (n = 
347)
Controls (n = 
581)
ORa (95% 
CI)
Age at menarcheb
<13 years 186 323 1.00 68 123 1.00 118 200 1.00
≥ 13 years 338 580 1.00 (0.80–
1.27)
112 199 1.01 (0.67–
1.51)
226 381 1.00 (0.75–
1.34)
Age at menarche, nulliparous women
<13 years 43 64 1.00 17 24 1.00 26 40 1.00
≥ 13 years 79 135 0.79 (0.48–
1.31)
24 46 0.98 (0.38–
2.55)
55 89 0.91 (0.47–
1.78)
Age at menarche, parous women
<13 years 143 259 1.00 51 99 1.00 92 160 1.00
≥ 13 years 259 445 1.11 (0.85–
1.45)
88 153 1.08 (0.68–
1.72)
171 292 1.09 (0.78–
1.53)
Pill usec
Never 85 178 1.00 30 62 1.00 55 116 1.00
Ever 442 724 1.23 (0.91–
1.66)
150 260 1.22 (0.72–
2.09)
292 464 1.24 (0.86–
1.79)
Pill use, nulliparous women
Never 25 48 1.00 10 23 1.00 15 25 1.00
Ever 99 150 1.64 (0.87–
3.08)
31 46 2.60 (0.81–
8.43)
68 104 1.35 (0.59–
3.10)
Pill use, parous women
Never 60 130 1.00 20 39 1.00 40 91 1.00
Ever 343 574 1.26 (0.89–
1.80)
119 214 1.10 (0.58–
2.09)
224 360 1.35 (0.88–
2.05)
Age at first full-term preganancyd
<25 years 215 352 1.00 69 125 1.00 146 227 1.00
≥ 25 years 188 353 0.86 (0.66–
1.14)
70 128 0.98 (0.60–
1.59)
118 225 0.79 (0.56–
1.11)
Breastfeeding statusd
Never 116 187 1.00 43 65 1.00 73 122 1.00
Ever 287 518 0.90 (0.68–
1.20)
96 188 0.70 (0.43–
1.16)
191 330 1.02 (0.71–
1.46)
Total months of breastfeeding among parous ever breastfed women
1–12 253 416 1.00 86 156 1.00 167 260 1.00
>12 34 102 0.56 (0.36–
0.87)
10 32 0.69 (0.30–
1.60)
24 70 0.53 (0.31–
0.90)
aMultivariate adjusted odds ratio (OR) and 95% confidence interval (CI). Adjusted for alcohol consumption (0, 1 to 18, >18 g/day); current body 
mass index as continuous variable; educational level (low, middle, high); family history of breast cancer in first-degree relative (no, yes); parity (0, 1 
to 2 births, 3+ births), and other variables in the table where appropriate. bThree cases and one control had missing data. cTwo controls had 
missing data. dLimited to parous women.Breast Cancer Research    Vol 7 No 4    Verla-Tebit et al.
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We did not find any evidence of an association between
CYP17 genotype and stage of breast cancer, with 65.5% of
those with local disease and 68.1% of those with the
advanced disease, respectively, being carriers of the A2 allele.
Discussion
The impact of CYP17 genetic polymorphism on the risk of
breast cancer gained a lot of interest after Feigelson and col-
leagues first reported an increase in risk of advanced breast
cancer for carriers of the A2 allele [8]. With a few exceptions
[19,26], most subsequent studies did not find an overall
increase in risk with the A2/A2 genotype [17,21,22,24,27-
31]. The A2 allele has been shown to be associated with
higher levels of estrogen in two studies [13,14], although a
recent study did not observe higher levels of estrogen with the
A2 allele [32]. Hong and colleagues recently reported that in
premenopausal women, the A2 allele is associated with higher
levels of dehydroepiandrosterone sulfate, which is a precursor
to estrogens and androgens [15]. Despite the higher levels of
this precursor in these subjects, there was no corresponding
elevation of estradiol levels, which could be due partly to the
difficulty of assessing representative estrogen levels based on
a single measure [15,33].
We did not observe an overall increase in risk associated with
the A2/A2 genotype compared with the A1/A1 genotype.
However, we found an increased risk associated with the A2/
A2 compared with the A1/A1 genotype among nulliparous
women. This observation supports findings from a previous
study indicating that nulliparous women with the A2/A2 geno-
type have higher mean levels of serum estradiol than those
with the A1/A1 genotype [14]. Jernström and colleagues [34]
also found out that the urinary ratio of the less potent 2-hydrox-
yestrone to the more potent 16α -hydroxyestrone is lower
among nulliparous women with the A2/A2 genotype com-
pared with the A1/A1 genotype. A low urinary ratio of 2-
hydroxyestrone to 16α -hydroxyestrone has been reported to
be associated with increased risk of breast cancer in
premenopausal women [35]. This could explain our finding of
increased risk of nulliparous premenopausal women with the
A2/A2 genotype. Despite the biologically plausible mecha-
nisms, this result should be interpreted with caution, because
the numbers of subjects were small in this group and we did
not observe any significant gene–parity effect modification. An
increased risk has also been reported for nulliparous women
and women who had had their first full-term pregnancy after
the age of 30 years for carriers of at least one A2 allele among
Chinese women in Singapore, though this was more pro-
nounced in the postmenopausal group with that allele [24]. In
the same line, a lower risk was observed for parous women
with the A1/A1 genotype compared with nulliparous women
with the same genotype [22]. Altogether, these findings sug-
gest that the increased risk associated with A2 alleles may be
more easily observable in nulliparous women because the
greater lifetime exposure to circulating steroid hormones asso-
ciated with this genotype is not altered by reproductive events.
We found no evidence of the previously reported effect modi-
fication for later age at menarche by the A1/A1 genotype
[8,13,21,22]. We also did not find any association with
respect to age at first full-term pregnancy. These associations
were still absent after stratification by parity. A number of stud-
ies have also not been able to detect an association
[17,29,30], including one of the largest case–control studies
on this topic [31]. We observed an increased risk for oral con-
traceptive use compared with those who had never used oral
contraceptives among nulliparous women with the A1/A1 gen-
otype, although this might be a chance finding, especially as
the number of subjects in this subgroup was small. Selection
bias could also explain the findings if nulliparous case subjects
with the A1/A1 genotype who participated in the study are
more likely to use oral contraceptives. This is unlikely, however,
as subjects are aware neither of their own genetype nor of the
risk associated with it. Ambrosone and colleagues reported
similar findings, though this was for all premenopausal women
and not only in the nulliparous group [21]. They argued that
oral contraceptive use might affect risk only in an environment
of lower estrogens, seen in carriers of the A1/A1 genotype.
Among parous women who had ever breastfed, we found a
risk reduction for greater than 12 months of breastfeeding
compared with 1 to 12 months of breastfeeding, but this effect
did not differ with CYP17 genotype.
We also assessed the impact of CYP17 on stage of breast
cancer, and, as in other studies [22,30,31], we were not able
to confirm the increased risk for advanced breast cancer
reported previously [8,26]. The association with stage was
found in studies that included subjects having different racial
and ethnic backgrounds. However, a possible bias due to pop-
ulation stratification can be excluded, as this effect was
observed across all the ethnic groups [26].
We found fewer A2/A2 carriers in cases with a positive family
history of breast cancer in first-degree relatives than in all con-
trols, irrespective of family history of breast cancer (12.3% ver-
sus 17.4%; P = 0.21). This contradicts the findings of Spurdle
and colleagues [27], who observed more of the A2/A2 geno-
type among cases with a positive family history of breast can-
cer in first- or second-degree relatives than in all controls. Their
study subjects were below the age of 40, whereas most of our
study subjects (70%) were aged 40 or above. In addition, they
reported a deviation from Hardy–Weinberg equilibrium among
cases with a positive family history of breast cancer, whereas
we did not observe a deviation in this group (χ 2 = 0.25; P =
0.62). Jernström and colleagues in their study on nulliparous
young women also reported that carriers of the A2/A2 geno-
type had less family history of breast cancer in first- or second-
degree relatives than carriers of the A1/A2 and A1/A1 geno-
types combined [34].Available online http://breast-cancer-research.com/content/7/4/R455
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Conclusion
Our results do not suggest a major influence of CYP17
genetic polymorphism on the risk of premenopausal breast
cancer generally, but they do suggest an increase in risk for
nulliparous women with the A2/A2 genotype. The resolution of
the question regarding the role of the CYP17 genotype in
breast cancer risk may require a better understanding of the
functional variants discussed. A more comprehensive haplo-
type analysis would help to clarify whether the CYP17 variant
allele itself is causal or is in linkage disequilibrium with some
other variant that has a causal relation with breast cancer.
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